Table 4.

Clinical characteristics, therapeutic response, and toxicities of the 11 patients presenting with detectable baseline HIV RNA (n = 9) and/or advanced immunosuppression (n = 4).

Patient	Sex	Age (years)	Cancer and stage	PD-1 inhibitor	HIV RNA at baseline (copies/mL)	HIV RNA after PD-1 inhibitors (copies/mL)	CD4+ T-cell count at baseline (cells/μL)	CD4+ T-cell count at 24 weeks (cells/μL)	Response	Toxicity
1	Male	35	Lung cancer III	Tislelizumab	13,932	ND	122	179	PD	NO
2	Male	69	Lung cancer III	Sintilimab	1.62 × 105	ND	210	219	SD	NO
3	Male	69	Lung cancer III	Sintilimab	6,754	ND	318	402	SD	Hypothyroidism
4	Male	51	Liver cancer III	Sintilimab	1,323	ND	165	258	PD	Hypothyroidism
5a	Male	78	Lung cancer IV	Camrelizumab	1.04 × 106	NA	36	248	SD	NO
6	Male	55	Esophageal cancer III	Camrelizumab	59	ND	321	345	PD	Hypothyroidism
7	Male	48	Esophageal cancer IV	Camrelizumab	41	NA	399	400	SD	NO
8a	Male	55	Esophageal cancer IV	Tislelizumab	542	54	69	154	PD	NO
9	Male	27	Gastric cardia adenocarcinoma IV	Sintilimab	3,049	44	208	282	PD	NO
10	Male	63	Lung cancer III	Tislelizumab	ND	ND	49	135	PD	NO
11	Male	69	Nasopharyngeal carcinoma III	Camrelizumab	ND	ND	73	137	PD	NO

^aPatients 5 and 8 had detectable HIV RNA and concurrent CD4+ T-cell counts < 100 cells/μL at baseline.

NA, not available; ND, not detected; NO, not observed.